Form 4: Immuneering CSO Brett Hall Granted Stock Options

Immuneering Corp's Chief Scientific Officer, Brett Matthew Hall, was granted 344,000 stock options with a strike price of $4.91, vesting over four years.

Summary

• Chief Scientific Officer Brett Matthew Hall of Immuneering Corp (IMRX) was granted 344,000 stock options.
• The exercise price for these options is $4.91 per share.
• The options were granted on February 3, 2026.
• They vest in equal monthly installments over a four-year period, commencing on February 1, 2026.
• The options will be fully vested and exercisable on January 1, 2030.
• The expiration date for these stock options is February 3, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for corporate governance and executive incentive alignment, as it ties a key executive's long-term compensation directly to the company's stock performance.

Positives

• The grant of 344,000 stock options to the Chief Scientific Officer aligns management incentives with shareholder value.
• The four-year vesting schedule encourages long-term commitment and performance from a key executive.

Negatives

• There is no immediate cash benefit to the executive, as these are options, not shares.
• The value of the options is dependent on the future stock price exceeding the $4.91 exercise price.

Risks

• The value of the stock options is contingent on Immuneering Corp's stock price exceeding the $4.91 exercise price by the expiration date.

Future Outlook

The stock options granted to the Chief Scientific Officer will vest in equal monthly installments over a four-year period, commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like a Chief Scientific Officer is a common practice in the biotechnology and pharmaceutical industries to incentivize long-term performance and align executive interests with shareholder value, especially in companies focused on research and development like Immuneering Corp.

Comparison to Industry Standards

• The four-year vesting schedule is a standard practice for executive stock option grants across various industries, including biotech, aligning with typical employee retention and performance cycles.
• The grant size of 344,000 options for a CSO is significant and suggests a strong commitment to retaining and motivating key scientific leadership, comparable to grants seen in similar-stage biotech companies.

Related Party Transactions

• Grant of stock options to Chief Scientific Officer Brett Matthew Hall as part of executive compensation.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with shareholder value through performance-based compensation.
• Employees: May signal confidence in the company's future and its ability to retain key talent.

Next Steps

• The options will begin vesting on February 1, 2026.
• The options will be fully vested and exercisable on January 1, 2030.
• The options will expire on February 3, 2036.

Key Dates

Keywords

Immuneering Corp, IMRX, Stock Options, Executive Compensation, Form 4, Brett Matthew Hall, Chief Scientific Officer, Insider Transaction